Valencia, California – Newsfile Corp. – 17 November 2022 – On September 28, 2022, AVITA Medical, Inc. appointed Jim Corbett as Chief Executive Officer, effective immediately. Mr. Corbett, who has served as a non-executive member of the Board of Directors, will continue as an executive member of the Board of Directors of AVITA Medical, Inc. James ‘Jim’ Corbett is a career life sciences executive, and he brings over 30 years of experience building and running commercial-stage healthcare business, including serving as CEO of three publicly traded companies.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Throughout Jim’s career, he has served as CEO of 3 publicly traded companies: MTIX (Microtherapeutics), ev3, and Alphatec Spine.
  • During his time as GM Baxter Japan, he grew operating earnings from 2.5x annually over three years.
  • While he was GM/President, SciMed was acquired by Boston Scientific.
Meet Jim Corbett - Chief Executive Officer, AVITA Medical, Inc.


Click image above to view full announcement.




ABOUT AVITA MEDICAL, INC.

is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin cells. Delivered at the point-of-care, RECELL enables improved clinical outcomes and validated cost savings. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications, including soft tissue repair and repigmentation of stable vitiligo lesions.

AVITA Medical’s first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. In February 2022, the FDA reviewed and approved the PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.

The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 15,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL Autologous Cell Harvesting Device () for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, soft tissue repair, vitiligo, and aesthetics. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan. To learn more, visit .

Services

Upcoming Events

MGBF In The News